Congenital myasthenic syndromes: Difficulties in the diagnosis, course and prognosis, and therapy - The French national Congenital Myasthenic Syndrome network experience;Syndromes myasthéniques congénitaux: difficultés diagnostiques, évolution et pronostic, thérapeutique L'expérience du réseau national « Syndromes Myasthéniques Congénitaux »

Revue Neurologique

Volumn 169, Issue SUPPL.1, 2013, Pages

  Eymard, B ^a   Stojkovic, T ^a   Sternberg, D ^a   Richard, P ^a   Nicole, S ^a   Fournier, E ^a   Behin A ^a   Laforet P ^a   Servais, L ^a   Romero, N ^a   Fardeau, M ^a   Hantai D ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cholinesterase inhibitors; Congenital myasthenic syndromes; Ephedrine; Therapy

Indexed keywords

CHOLINESTERASE INHIBITOR; EPHEDRINE;

ARTICLE; ATROPHY; CONGENITAL MYASTHENIC SYNDROME; DISEASE EXACERBATION; GENE MUTATION; HUMAN; LIPIDOSIS; MUSCLE WEAKNESS; PROGNOSIS; SCOLIOSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED DIAGNOSIS; DIAGNOSTIC ERRORS; DISEASE PROGRESSION; EPHEDRINE; FEMALE; FRANCE; HUMANS; INFORMATION CENTERS; MALE; MIDDLE AGED; MYASTHENIC SYNDROMES, CONGENITAL; PREGNANCY; PROGNOSIS; YOUNG ADULT;

EID: 84875633748     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-3787(13)70060-2     Document Type: Article

References (50)

1. D. Beeson, O. Higuchi, J. Palace, J. Cossins, H. Spearman, and S. Maxwell Dok-7 mutations underlie a neuromuscular junction synaptopathy Science 313 2006 1975 1978 (Pubitemid 44498007)
2. A. Béhin, M. Mayer, B. Kassis-Makhoul, M. Jugie, C. Espil-Taris, and X. Ferrer Severe neonatal myasthenia due to maternal anti-MuSK antibodies Neuromuscul Disord 18 2008 443 446
3. K. Belaya, S. Finlayson, C.R. Slater, J. Cossins, W.W. Liu, and S. Maxwell Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates Am J Hum Genet 91 2012 193 201
4. A. Ben Ammar, F. Petit, N. Alexandri, K. Gaudon, S. Bauché, and A. Rouche Phenotype genotype analysis in 15 patients presenting a congenital myasthenic syndrome due to mutations in DOK7 J Neurol 257 2010 754 766
5. C.M. Bowe, D.Z. Kong, R. Wollmann, and R.A. Maselli In vitro effect of 3, 4-diaminopyridine (3, 4-DAP) on neuromuscular transmission in muscle biopsies of patient with different types of congenital myasthenic syndromes (CMS) Neurology 54 2000 S65.006
6. G. Burke, J. Cossins, S. Maxwell, G. Owens, A. Vincent, and S. Robb Rapsyn mutations in hereditary myasthenia: distinct earlyand late-onset phenotypes Neurology 61 2003 826 828 (Pubitemid 37174482)
7. A. Chaouch, D. Beeson, D. Hantaï, and H. Lochmüller 186th ENMC International Workshop: Congenital myasthenic syndromes 24-26 June 2011, Naarden, The Netherlands Neuromuscul Disord 22 2012 566 576
8. A. Chaouch, J. Müller, V. Guergeltcheva, M. Dusl, U. Schiara, and V. Rakocevic-Stojanic A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome J Neurol 259 2012 474 481
9. F. Chevessier, B. Faraut, A. Ravel-Chapuis, P. Richard, K. Gaudon, and S. Bauché MUSK, a new target for mutations causing congenital myasthenic syndrome Hum Mol Genet 13 2004 3229 3240 (Pubitemid 40045274)
10. T.M. De Chiara, D.C. Bowen, D.M. Valenzuela, M.V. Simmons, W.T. Poueymirou, and S. Thomas The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo Cell 85 1996 501 512 (Pubitemid 26157189)
11. C. Donger, E. Krejci, A.P. Serradell, B. Eymard, S. Bon, and S. Nicole Mutation in the human acetylcholinesterase-associated collagen gene. COLQ, is responsible for congenital myasthenic syndrome with end-plate acetylcholinesterase deficiency (Type Ic) Am J Hum Genet 63 1998 7 75
12. A.G. Engel, E.H. Lambert, and M.R. Gomez A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release Ann Neurol 1 1977 315 330
13. A.G. Engel The therapy of congenital myasthenic syndrome Neurotherapeutics 4 2007 252 257
14. A.G. Engel, and S.M. Sine Current understanding of congenital myasthenic syndromes Curr Opin Pharmacol 5 2005 308 321 (Pubitemid 40674255)
15. B. Eymard Neonatal myasthenia gravis clinical and pathophysiological aspects Adv Organ Biol 2 1997 235 247
16. T. Fukudome, K. Ohno, J.M. Brengman, and A.G. Engel Quinidine normalizes the open duration of slow-channel mutants of the acetylcholine receptor NeuroReport 9 1998 1907 1911 (Pubitemid 28289208)
17. M. Gautam, P.G. Noakes, J. Mudd, M. Nichol, G.C. Chu, and J.R. Sanes Failure of postsynaptic specialization to develop at neuromuscular junctions in rapsyn-deficient mice Nature 377 1995 232 236
18. V. Guergueltcheva, J.S. Müller, M. Dusl, J. Senderek, A. Oldfors, and C. Lindbergh Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations J Neurol 259 2012 838 850
19. C.M. Harper, A.G. Engel, and T. Fukudome Treatment of slow channel congenital myasthenic syndrome with fluoxetine Neurology 60 2003 1710 1713 (Pubitemid 36618113)
20. C. Huzé, S. Bauché, P. Richard, F. Chevessier, E. Goillot, and K. Gaudon Identification of a mutation in agrin that causes congenital myasthenia and affects synapse function Am J Hum Genet 85 2009 155 167
21. C. Ioos, A. Barois, P. Richard, B. Eymard, D. Hantaï, and B. Estournet-Mathiaud Congenital myasthenic syndrome due to rapsyn deficiency: three cases with artrogryposis and bulbar symptoms Neuropediatrics 35 2004 246 249 (Pubitemid 39215605)
22. K. Ishigaki, D. Nicolle, E. Krejci, J.P. Leroy, J. Koenig, and M. Fardeau Two novel mutations in the ColQ gene cause endplate acetylcholinesterase deficiency Neuromusc Disord 13 2003 236 244 (Pubitemid 36279428)
23. P.Y. Jeannet, G. Bassez, B. Eymard, P. Laforêt, J.A. Urtizberea, and A. Rouche Clinical and histologic findings in autosomal centronuclear myopathy Neurology 11 62 2004 1484 1490 (Pubitemid 38608183)
24. P.Y. Jeannet, J.P. Marcoz, T. Kuntzer, and E. Roulet-Perez Isolated facial and bulbar paresis: a persistent manifestation of neonatal myasthenia gravis Neurology 15 70 2008 237 238
25. H. Jungluth, H. Zhou, L. Hartley, B. Halliger-Keller, S. Messina, and C. Longman Minicore myopathy with ophtalmolegia caused by mutations in the ryanodine receptor type 1 gene Neurology 65 2005 1930 1935 (Pubitemid 43970113)
26. D. Lashley, J. Palace, S. Jayawant, S. Robb, and D. Beeson Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7 Neurology 74 2010 1517 1523
27. T. Liewluck, D. Selcen, and A. Engel Beneficial effects of Albuterol in congenital endplate acetylcholisetrase deficiency and Dok-7 myasthenia Muscle Nerve 44 2011 789 794
28. R.A. Maselli, J.J. Ng, J.A. Anderson, O. Cagney, J. Arredondo, and C. Williams et al Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome J Med 46 2009 203 208
29. V. Mihaylova, J.S. Müller, J.J. Vichez, M.A. Salih, M.M. Kabiraj, and A. D'Amico Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes Brain 131 2008 747 759 (Pubitemid 351294715)
30. M. Milone, X.M. Shen, D. Selcen, K. Ohno, J. Brengman, and S.T. Iannaccone Myasthenic syndrome due to defects in rapsyn: Clinical and molecular findings in 39 patients Neurology 73 2009 228 235
31. J. Molgo, H. Lundh, and S. Thelseff Potency of 3, 4-diainopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes Eur J Phamacol 61 1980 25 34 (Pubitemid 10178022)
32. B. Morar, D. Gresham, D. Angelicheva, I. Tournev, R. Gooding, and V. Guergueltcheva Mutation history of the Roma/Gypsies Am J Hum Genet 75 2004 596 609 (Pubitemid 39244774)
33. E. Morel, B. Eymard, B. Vernet-der Garabedian, C. Pannier, O. Dulac, and J.F. Bach Neonatal myasthenia gravis: a new clinical and immunologic appraisal on 30 cases Neurology 38 1988 138 142 (Pubitemid 18028108)
34. J.S. Müller, G. Mildner, W. Müller-Felber, U. Schara, K. Krampfl, and B. Petersen Rapsyn N88K is a frequent cause of congenital myasthenic syndromes in European patients Neurology 60 2003 1805 1810 (Pubitemid 36737078)
35. J. Müller, A. Herczegfalvi, J.J. Vilchez, U. Schara, K. Krampfl, and B. Petersen Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes Brain 130 2007 1497 1506 (Pubitemid 47355920)
36. K. Ohno, A.G. Engel, J.M. Brengman, X.M. Shen, F. Heidenreich, and A. Vincent The spectrum of mutations causing endplate acetylcholinesterase deficiency Ann Neurol 47 2000 162 170 (Pubitemid 30078562)
37. K. Ohno, A.G. Engel, X.M. Shen, D. Selcen, J. Brengman, and C.M. Harper Rapsyn mutations in humans cause endplate acetylcholinereceptor deficiency and myasthenic syndrome Am J Hum Genet 70 2002 875 885 (Pubitemid 34259304)
38. K. Okada, A. Inoue, A. Okada, Y. Murata, S. Kakuta, and T. Jigami The muscle protein Dok-7 is essential for neuromuscular synaptogenesis Science 312 2006 1802 1805 (Pubitemid 43962899)
39. H. Oosterhuis, J. Newsom-Davis, J. Wokke, P.C. Molenaar, T.V. Weerden, and B.S. Oen The slow channel syndrome. Two new cases Brain 110 1987 1061 1079 (Pubitemid 17135226)
40. O. Outteryck, P. Richard, A. Lacour, E. Fournier, H. Zéphir, and K. Gaudon Novel epsilon subunit mutation of the muscle acetylcholine receptor causing a slow-channel congenital myasthenic syndrome J Neurol Neurosurg Psychiatry 80 2009 450 451
41. J. Palace, D. Lashley, J. Newsom-Davis, J. Cossins, S. Maxwell, and R. Kennett Clinical features of DOK7 neuromuscular junction synaptopathy Brain 130 2007 1507 1515 (Pubitemid 47355922)
42. P. Richard, K. Gaudon, F. Andreux, E. Yasaki, C. Prioleau, and S. Bauché Possible founder effect of rapsyn N88K mutation and identification of novel rapsyn mutations in congenital myasthenic syndromes J Med Genet 40 2003 e81 e85
43. P. Richard, K. Gaudon, H. Haddad, A.B. Ammar, E. Genin, and S. Bauché The CHRNE 1293insG founder mutation is a frequent cause of congenital myasthenia in North Africa Neurology 71 2008 1967 1972
44. L. Servais, H. Baudoin, K. Zehrouni, P. Richard, D. Sternberg, and E. Fournier Pregnancy in congenital myasthenic syndrom. J Neurol 2012 [Epub ahead of print]
45. U. Schara, and H. Lochmüller Therapeutic strategies in congenital myasthenic syndromes Neurotherapeutics 5 2008 542 547
46. U. Schara, N. Barisic, M. Deschauer, C. Lindberg, V. Straub, and N. Strigl-Pill Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations Neuromuscul Disord 19 2009 828 832
47. D. Selcen, M. Milone, X.M. Shen, C.M. Harper, A.A. Stans, and E.D. Wieben et al Dok-7 myasthenia: phenotypic and molecular genetic studies in 16 patients Ann Neurol 64 2008 71 87
48. J. Senderek, J.S. Müller, M. Dusl, T.M. Strom, V. Guergueltcheva, and Diepolder Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect Am J Hum Genet 88 2011 162 172
49. M. Srour, V. Bolduc, V. Guergueltcheva, H. Lochmüller, D. Gendron, and M.I. Shevell DOK7 mutations presenting as a proximal myopathy in French Canadians Neuromuscul Disord 20 2010 453 457
50. I. Wargon, P. Richard, T. Kuntzer, D. Sternberg, S. Nafissi, and K. Gaudon Long-term follow-up of patients with congenital myasthenic syndrome caused by COLQ mutations Neuromuscul Disord 22 2012 318 324